董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Neil Klompas | 男 | Independent Director | 54 | 4.45万美元 | 0.13 | 2026-09-29 |
| Andrew Hull | 男 | Independent Director and Chair of the Board | 63 | 6.87万美元 | 0.22 | 2026-09-29 |
| Eric A. Adams | 男 | Chief Executive Officer, Director and President | 62 | 37.93万美元 | 2.43 | 2026-09-29 |
| Nicole Lemerond | 女 | Independent Director | 50 | 5.80万美元 | 0.10 | 2026-09-29 |
| John Bathery | 男 | Independent Director | 56 | 4.02万美元 | 0.13 | 2026-09-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Eric A. Adams | 男 | Chief Executive Officer, Director and President | 62 | 37.93万美元 | 2.43 | 2026-09-29 |
| Eric Hsu | 男 | Senior Vice President, Preclinical Research & Development | 56 | 30.56万美元 | 0.81 | 2026-09-29 |
| Michael Woudenberg | 男 | Chief Operating Officer | 57 | 32.97万美元 | 1.14 | 2026-09-29 |
| Netta Jagpal | 女 | Chief Financial Officer and Corporate Secretary | 53 | 29.59万美元 | 1.02 | 2026-09-29 |
董事简历
中英对照 | 中文 | 英文- Neil Klompas
-
Neil Klompas在医疗保健和生物技术领域已有30多年的历史，担任过多个高级领导职务，涉及运营、财务和研发职责。目前，他是Augurex Lifesciences Inc.的总裁兼首席执行官和董事，Augurex Lifesciences Inc.是一家私营的自身免疫诊断公司。最近，他担任Zymeworks（纳斯达克股票代码：ZYME）的总裁兼首席运营官，此前他曾在该公司担任首席财务官等职务。在此之前，Klompas先生的经历包括在美国和加拿大的全球金融服务公司毕马威担任职务，在那里他为制药、生物技术和医疗设备部门的交易和金融业务提供咨询。Klompas先生在NervGen Pharma（纳斯达克：NGEN）和HTUO Biosciences的董事会担任董事，并曾担任多家生物技术公司的董事和顾问，包括曾担任Ovensa Inc.的董事会主席，以及Liminal Biotherapeutics的董事会成员。Klompas先生拥有不列颠哥伦比亚大学理学学士学位，是一名特许会计师和特许专业会计师。他在生物科技公司创立、资金、治理、融资和战略增长等各个方面的丰富经验将是对公司的宝贵贡献。
Neil Klompas has been involved in healthcare and biotechnology for over 30 years in various senior leadership roles spanning operational, financial and research and development responsibilities. Currently, he is President and CEO and a Director at Augurex Lifesciences Inc., a privately held autoimmune diagnostics company. Most recently, he served as President and Chief Operating Officer of Zymeworks (NASDAQ: ZYME), where he had previously held the role of Chief Financial Officer among other positions. Prior to that, Mr. Klompas' experience included roles with KPMG, a global financial services firm, in both the United States and Canada where he advised on transactions and financial engagements across the pharmaceuticals, biotechnology and medical devices sectors. Mr. Klompas serves as a director on the boards of NervGen Pharma (Nasdaq: NGEN) and HtuO Biosciences, and has served as a director and advisor to various biotechnology companies, including previously serving as board Chair for Ovensa Inc., and on the board of Liminal Biotherapeutics. Mr. Klompas holds a Bachelor of Science degree from the University of British Columbia, and is a Chartered Accountant and Chartered Professional Accountant. His extensive experience in all aspects of biotechnology company founding, funding, governance, financing and strategic growth will be valuable contributions to the Company. - Neil Klompas在医疗保健和生物技术领域已有30多年的历史，担任过多个高级领导职务，涉及运营、财务和研发职责。目前，他是Augurex Lifesciences Inc.的总裁兼首席执行官和董事，Augurex Lifesciences Inc.是一家私营的自身免疫诊断公司。最近，他担任Zymeworks（纳斯达克股票代码：ZYME）的总裁兼首席运营官，此前他曾在该公司担任首席财务官等职务。在此之前，Klompas先生的经历包括在美国和加拿大的全球金融服务公司毕马威担任职务，在那里他为制药、生物技术和医疗设备部门的交易和金融业务提供咨询。Klompas先生在NervGen Pharma（纳斯达克：NGEN）和HTUO Biosciences的董事会担任董事，并曾担任多家生物技术公司的董事和顾问，包括曾担任Ovensa Inc.的董事会主席，以及Liminal Biotherapeutics的董事会成员。Klompas先生拥有不列颠哥伦比亚大学理学学士学位，是一名特许会计师和特许专业会计师。他在生物科技公司创立、资金、治理、融资和战略增长等各个方面的丰富经验将是对公司的宝贵贡献。
- Neil Klompas has been involved in healthcare and biotechnology for over 30 years in various senior leadership roles spanning operational, financial and research and development responsibilities. Currently, he is President and CEO and a Director at Augurex Lifesciences Inc., a privately held autoimmune diagnostics company. Most recently, he served as President and Chief Operating Officer of Zymeworks (NASDAQ: ZYME), where he had previously held the role of Chief Financial Officer among other positions. Prior to that, Mr. Klompas' experience included roles with KPMG, a global financial services firm, in both the United States and Canada where he advised on transactions and financial engagements across the pharmaceuticals, biotechnology and medical devices sectors. Mr. Klompas serves as a director on the boards of NervGen Pharma (Nasdaq: NGEN) and HtuO Biosciences, and has served as a director and advisor to various biotechnology companies, including previously serving as board Chair for Ovensa Inc., and on the board of Liminal Biotherapeutics. Mr. Klompas holds a Bachelor of Science degree from the University of British Columbia, and is a Chartered Accountant and Chartered Professional Accountant. His extensive experience in all aspects of biotechnology company founding, funding, governance, financing and strategic growth will be valuable contributions to the Company.
- Andrew Hull
-
Andrew Hull自2016年9月起担任公司董事。赫尔先生最近于2014年至2018年担任武田制药的全球联盟主管，负责最大限度地促进武田与许多行业领先的制药和生物技术公司建立越来越多（40 +）的商业和研发合作伙伴关系的成功。赫尔先生曾担任营销高级副总裁以及业务发展和战略产品规划高级副总裁，曾领导武田超过30亿美元的美国投资组合的营销和商业开发，并领导了包括许可和收购在内的合作活动。此外，他还在Immunex和雅培担任过越来越重要的职务。赫尔先生于1985年获得肯扬学院生物学学士学位。他最近还担任伊利诺伊州生物技术创新组织InMed董事会成员，曾担任该组织两届主席，最近还担任肯扬学院董事会成员。赫尔先生最近担任Zucara Therapeutics的董事。Hull先生基于在领先的制药和生物技术公司担任各种商业和业务发展职务的30多年经验，为InMed董事会做出了宝贵贡献。
Andrew Hull has been a director of the company since September 2016. Mr. Hull most recently served as Head of Global Alliances for Takeda Pharmaceuticals from 2014 to 2018, where he was responsible for maximizing the success of Takeda's growing number (40+) of commercial and research and development partnerships with many of the industry's leading pharmaceutical and biotech companies. In previous roles as Senior Vice President, Marketing, and Senior Vice President, Business Development and Strategic Product Planning, Mr. Hull led marketing and commercial development of Takeda's U.S. portfolio of over $3 billion and led partnering activities including licensing and acquisitions. Additionally, he held positions of increasing responsibility at Immunex and Abbott Laboratories. Mr. Hull received a Bachelor's degree in Biology from Kenyon College in 1985. He also recently served as a member of the InMed Board of the Illinois Biotechnology Innovation Organization, where he served two terms as chairman, and recently was a member of the Kenyon College Board of Trustees. Mr. Hull recently served as a director of Zucara Therapeutics. Mr. Hull makes valuable contributions to the InMed Board based on his over 30 years of experience in various commercial and business development roles with leading pharmaceutical and biotech companies. - Andrew Hull自2016年9月起担任公司董事。赫尔先生最近于2014年至2018年担任武田制药的全球联盟主管，负责最大限度地促进武田与许多行业领先的制药和生物技术公司建立越来越多（40 +）的商业和研发合作伙伴关系的成功。赫尔先生曾担任营销高级副总裁以及业务发展和战略产品规划高级副总裁，曾领导武田超过30亿美元的美国投资组合的营销和商业开发，并领导了包括许可和收购在内的合作活动。此外，他还在Immunex和雅培担任过越来越重要的职务。赫尔先生于1985年获得肯扬学院生物学学士学位。他最近还担任伊利诺伊州生物技术创新组织InMed董事会成员，曾担任该组织两届主席，最近还担任肯扬学院董事会成员。赫尔先生最近担任Zucara Therapeutics的董事。Hull先生基于在领先的制药和生物技术公司担任各种商业和业务发展职务的30多年经验，为InMed董事会做出了宝贵贡献。
- Andrew Hull has been a director of the company since September 2016. Mr. Hull most recently served as Head of Global Alliances for Takeda Pharmaceuticals from 2014 to 2018, where he was responsible for maximizing the success of Takeda's growing number (40+) of commercial and research and development partnerships with many of the industry's leading pharmaceutical and biotech companies. In previous roles as Senior Vice President, Marketing, and Senior Vice President, Business Development and Strategic Product Planning, Mr. Hull led marketing and commercial development of Takeda's U.S. portfolio of over $3 billion and led partnering activities including licensing and acquisitions. Additionally, he held positions of increasing responsibility at Immunex and Abbott Laboratories. Mr. Hull received a Bachelor's degree in Biology from Kenyon College in 1985. He also recently served as a member of the InMed Board of the Illinois Biotechnology Innovation Organization, where he served two terms as chairman, and recently was a member of the Kenyon College Board of Trustees. Mr. Hull recently served as a director of Zucara Therapeutics. Mr. Hull makes valuable contributions to the InMed Board based on his over 30 years of experience in various commercial and business development roles with leading pharmaceutical and biotech companies.
- Eric A. Adams
-
Eric A. Adams自2016年以来一直担任总裁兼首席执行官，并担任InMed的董事。Adams先生是一位经验丰富的生物制药高管，在公司和资本形成、全球市场开发、并购、许可和公司治理方面拥有超过30年的经验。在2011年至2016年期间，Adams先生担任多家生物制药和创新技术公司的导师和高级顾问。他此前曾在2004年至2011年期间担任EnGene Inc.的首席执行官和董事。在加入EnGene之前，他曾在QLT Inc.、Advanced Tissue Sciences Inc.、雅培、Fresenius AG担任全球市场开发高级职务。他拥有加拿大和美国双重国籍，拥有南卡罗来纳大学国际商务硕士学位和南印第安纳大学化学学士学位。Adams先生基于他在广泛的疾病类别中的丰富国际业务发展经验以及在制药和医疗器械领域不断发展的多个组织所做的贡献，为InMed董事会做出了宝贵的贡献。
Eric A. Adams has been the President and Chief Executive Officer, and a Director of InMed since 2016. Mr. Adams is a seasoned biopharmaceutical executive with over 30 years' experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During the period from 2011 to 2016, Mr. Adams served as a mentor and senior consultant to several biopharmaceutical and innovative technology companies. He previously served as Chief Executive Officer and Director at EnGene Inc. between 2004 and 2011. Prior to EnGene, he held senior roles in global market development with QLT Inc., Advanced Tissue Sciences Inc., Abbott Laboratories, and Fresenius AG. He is a dual citizen of Canada and the United States and holds a Master of International Business degree from the University of South Carolina and a Bachelor's degree in Chemistry from the University of Southern Indiana. Mr. Adams makes valuable contributions to the InMed Board based on his extensive international business development experience in a wide range of disease categories and contributions to growing several organizations across the pharmaceutical and medical device arenas. - Eric A. Adams自2016年以来一直担任总裁兼首席执行官，并担任InMed的董事。Adams先生是一位经验丰富的生物制药高管，在公司和资本形成、全球市场开发、并购、许可和公司治理方面拥有超过30年的经验。在2011年至2016年期间，Adams先生担任多家生物制药和创新技术公司的导师和高级顾问。他此前曾在2004年至2011年期间担任EnGene Inc.的首席执行官和董事。在加入EnGene之前，他曾在QLT Inc.、Advanced Tissue Sciences Inc.、雅培、Fresenius AG担任全球市场开发高级职务。他拥有加拿大和美国双重国籍，拥有南卡罗来纳大学国际商务硕士学位和南印第安纳大学化学学士学位。Adams先生基于他在广泛的疾病类别中的丰富国际业务发展经验以及在制药和医疗器械领域不断发展的多个组织所做的贡献，为InMed董事会做出了宝贵的贡献。
- Eric A. Adams has been the President and Chief Executive Officer, and a Director of InMed since 2016. Mr. Adams is a seasoned biopharmaceutical executive with over 30 years' experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During the period from 2011 to 2016, Mr. Adams served as a mentor and senior consultant to several biopharmaceutical and innovative technology companies. He previously served as Chief Executive Officer and Director at EnGene Inc. between 2004 and 2011. Prior to EnGene, he held senior roles in global market development with QLT Inc., Advanced Tissue Sciences Inc., Abbott Laboratories, and Fresenius AG. He is a dual citizen of Canada and the United States and holds a Master of International Business degree from the University of South Carolina and a Bachelor's degree in Chemistry from the University of Southern Indiana. Mr. Adams makes valuable contributions to the InMed Board based on his extensive international business development experience in a wide range of disease categories and contributions to growing several organizations across the pharmaceutical and medical device arenas.
- Nicole Lemerond
-
Nicole Lemerond自2022年8月起担任公司董事。Lemerond女士是一位金融高管，在投资管理、私募股权、投资银行和杠杆金融领域拥有超过25年的经验。她在执行复杂交易、管理尽职调查流程、筹集资金和构建资产负债表方面拥有丰富的经验。在她的整个职业生涯中，Lemerond女士一直与上市和私营公司管理团队和董事会合作，以增加利益相关者的价值。她在领先的投资公司建立并领导了医疗保健集团，还曾在几家大型金融机构任职，包括雷曼兄弟和凯雷集团。Lemerond女士是GeoVax，Inc.（纳斯达克：GOVX）和MediciNova, Inc.（纳斯达克：MNOV）的董事会成员。Lemerond女士拥有美国康奈尔大学的理学学士学位，并且是CFA特许持有人。Lemerond女士基于她在投资管理方面的丰富经验以及她与管理团队合作以增加利益相关者价值的经验，为公司董事会做出了宝贵贡献。
Nicole Lemerond has been a director of the company since August 2022. Ms. Lemerond is a financial executive with over 25 years of experience in investment management, private equity, investment banking and leveraged finance. She has significant experience executing complex transactions, managing diligence processes, raising capital and structuring balance sheets. Throughout her career, Ms. Lemerond has worked with public and private company management teams and boards to increase stakeholder value. She established and led healthcare groups at leading investment firms and has also worked at several large financial institutions, including Lehman Brothers and The Carlyle Group. Ms. Lemerond is a member of the board of directors of GeoVax, Inc. (Nasdaq: GOVX) and MediciNova, Inc. (Nasdaq: MNOV). Ms. Lemerond holds a Bachelor of Science degree from Cornell University and is a CFA charterholder. Ms. Lemerond makes valuable contributions to the company's Board based on her extensive experience in investment management and her experience working with management teams to increase stakeholder value. - Nicole Lemerond自2022年8月起担任公司董事。Lemerond女士是一位金融高管，在投资管理、私募股权、投资银行和杠杆金融领域拥有超过25年的经验。她在执行复杂交易、管理尽职调查流程、筹集资金和构建资产负债表方面拥有丰富的经验。在她的整个职业生涯中，Lemerond女士一直与上市和私营公司管理团队和董事会合作，以增加利益相关者的价值。她在领先的投资公司建立并领导了医疗保健集团，还曾在几家大型金融机构任职，包括雷曼兄弟和凯雷集团。Lemerond女士是GeoVax，Inc.（纳斯达克：GOVX）和MediciNova, Inc.（纳斯达克：MNOV）的董事会成员。Lemerond女士拥有美国康奈尔大学的理学学士学位，并且是CFA特许持有人。Lemerond女士基于她在投资管理方面的丰富经验以及她与管理团队合作以增加利益相关者价值的经验，为公司董事会做出了宝贵贡献。
- Nicole Lemerond has been a director of the company since August 2022. Ms. Lemerond is a financial executive with over 25 years of experience in investment management, private equity, investment banking and leveraged finance. She has significant experience executing complex transactions, managing diligence processes, raising capital and structuring balance sheets. Throughout her career, Ms. Lemerond has worked with public and private company management teams and boards to increase stakeholder value. She established and led healthcare groups at leading investment firms and has also worked at several large financial institutions, including Lehman Brothers and The Carlyle Group. Ms. Lemerond is a member of the board of directors of GeoVax, Inc. (Nasdaq: GOVX) and MediciNova, Inc. (Nasdaq: MNOV). Ms. Lemerond holds a Bachelor of Science degree from Cornell University and is a CFA charterholder. Ms. Lemerond makes valuable contributions to the company's Board based on her extensive experience in investment management and her experience working with management teams to increase stakeholder value.
- John Bathery
-
John Bathery在不同职能和角色方面拥有超过30年的制药行业经验，其中包括超过15年的企业发展和合作伙伴责任。他被公认为是一位有效的领导者，有能力指导全球倡议以兑现认可的战略。John在领导企业评估和并购谈判、许可、外包许可、撤资和再谈判方面都有良好的记录，已完成的交易财务条款超过600亿美元。目前，他是武田制药的全球业务发展运营&外部化负责人。他于2008年加入武田的全球业务发展（GBD）团队。他之前在武田担任的职务包括领导美国业务部门、胃肠病学治疗领域以及免疫学和呼吸治疗领域的业务发展活动。他目前担任iBIO（伊利诺伊州生物技术创新组织）的董事会成员，自2018年起担任该职务。在加入武田之前，John曾在TAP Pharmaceuticals、Unimed Pharmaceuticals和雅培担任越来越多的职务。
John Bathery has over 30 years of pharmaceutical industry experience across diverse functions and roles, including more than 15 years with corporate development and partnership responsibilities. He is recognized as an effective leader with the ability to guide global initiatives to deliver on endorsed strategies. John has a proven record in leading business evaluations and negotiations across M&A, in licensing, out licensing, divestments, and re negotiations, having closed transactions with financial terms exceeding $60 billion. Currently, he is the head of Global Business Development Operations & Externalization at Takeda Pharmaceuticals. He joined Takeda's Global Business Development (GBD) team in 2008. His previous roles at Takeda include leading business development activities for the U.S. Business Unit, the gastroenterology therapeutic area, and the immunology & respiratory therapeutic area. He currently serves as a member of the board of directors for iBIO (Illinois Biotechnology Innovation Organization), a role he has held since 2018. Before joining Takeda, John held roles of increasing responsibility at TAP Pharmaceuticals, Unimed Pharmaceuticals, and Abbott Laboratories. - John Bathery在不同职能和角色方面拥有超过30年的制药行业经验，其中包括超过15年的企业发展和合作伙伴责任。他被公认为是一位有效的领导者，有能力指导全球倡议以兑现认可的战略。John在领导企业评估和并购谈判、许可、外包许可、撤资和再谈判方面都有良好的记录，已完成的交易财务条款超过600亿美元。目前，他是武田制药的全球业务发展运营&外部化负责人。他于2008年加入武田的全球业务发展（GBD）团队。他之前在武田担任的职务包括领导美国业务部门、胃肠病学治疗领域以及免疫学和呼吸治疗领域的业务发展活动。他目前担任iBIO（伊利诺伊州生物技术创新组织）的董事会成员，自2018年起担任该职务。在加入武田之前，John曾在TAP Pharmaceuticals、Unimed Pharmaceuticals和雅培担任越来越多的职务。
- John Bathery has over 30 years of pharmaceutical industry experience across diverse functions and roles, including more than 15 years with corporate development and partnership responsibilities. He is recognized as an effective leader with the ability to guide global initiatives to deliver on endorsed strategies. John has a proven record in leading business evaluations and negotiations across M&A, in licensing, out licensing, divestments, and re negotiations, having closed transactions with financial terms exceeding $60 billion. Currently, he is the head of Global Business Development Operations & Externalization at Takeda Pharmaceuticals. He joined Takeda's Global Business Development (GBD) team in 2008. His previous roles at Takeda include leading business development activities for the U.S. Business Unit, the gastroenterology therapeutic area, and the immunology & respiratory therapeutic area. He currently serves as a member of the board of directors for iBIO (Illinois Biotechnology Innovation Organization), a role he has held since 2018. Before joining Takeda, John held roles of increasing responsibility at TAP Pharmaceuticals, Unimed Pharmaceuticals, and Abbott Laboratories.
高管简历
中英对照 | 中文 | 英文- Eric A. Adams
Eric A. Adams自2016年以来一直担任总裁兼首席执行官，并担任InMed的董事。Adams先生是一位经验丰富的生物制药高管，在公司和资本形成、全球市场开发、并购、许可和公司治理方面拥有超过30年的经验。在2011年至2016年期间，Adams先生担任多家生物制药和创新技术公司的导师和高级顾问。他此前曾在2004年至2011年期间担任EnGene Inc.的首席执行官和董事。在加入EnGene之前，他曾在QLT Inc.、Advanced Tissue Sciences Inc.、雅培、Fresenius AG担任全球市场开发高级职务。他拥有加拿大和美国双重国籍，拥有南卡罗来纳大学国际商务硕士学位和南印第安纳大学化学学士学位。Adams先生基于他在广泛的疾病类别中的丰富国际业务发展经验以及在制药和医疗器械领域不断发展的多个组织所做的贡献，为InMed董事会做出了宝贵的贡献。
Eric A. Adams has been the President and Chief Executive Officer, and a Director of InMed since 2016. Mr. Adams is a seasoned biopharmaceutical executive with over 30 years' experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During the period from 2011 to 2016, Mr. Adams served as a mentor and senior consultant to several biopharmaceutical and innovative technology companies. He previously served as Chief Executive Officer and Director at EnGene Inc. between 2004 and 2011. Prior to EnGene, he held senior roles in global market development with QLT Inc., Advanced Tissue Sciences Inc., Abbott Laboratories, and Fresenius AG. He is a dual citizen of Canada and the United States and holds a Master of International Business degree from the University of South Carolina and a Bachelor's degree in Chemistry from the University of Southern Indiana. Mr. Adams makes valuable contributions to the InMed Board based on his extensive international business development experience in a wide range of disease categories and contributions to growing several organizations across the pharmaceutical and medical device arenas.- Eric A. Adams自2016年以来一直担任总裁兼首席执行官，并担任InMed的董事。Adams先生是一位经验丰富的生物制药高管，在公司和资本形成、全球市场开发、并购、许可和公司治理方面拥有超过30年的经验。在2011年至2016年期间，Adams先生担任多家生物制药和创新技术公司的导师和高级顾问。他此前曾在2004年至2011年期间担任EnGene Inc.的首席执行官和董事。在加入EnGene之前，他曾在QLT Inc.、Advanced Tissue Sciences Inc.、雅培、Fresenius AG担任全球市场开发高级职务。他拥有加拿大和美国双重国籍，拥有南卡罗来纳大学国际商务硕士学位和南印第安纳大学化学学士学位。Adams先生基于他在广泛的疾病类别中的丰富国际业务发展经验以及在制药和医疗器械领域不断发展的多个组织所做的贡献，为InMed董事会做出了宝贵的贡献。
- Eric A. Adams has been the President and Chief Executive Officer, and a Director of InMed since 2016. Mr. Adams is a seasoned biopharmaceutical executive with over 30 years' experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During the period from 2011 to 2016, Mr. Adams served as a mentor and senior consultant to several biopharmaceutical and innovative technology companies. He previously served as Chief Executive Officer and Director at EnGene Inc. between 2004 and 2011. Prior to EnGene, he held senior roles in global market development with QLT Inc., Advanced Tissue Sciences Inc., Abbott Laboratories, and Fresenius AG. He is a dual citizen of Canada and the United States and holds a Master of International Business degree from the University of South Carolina and a Bachelor's degree in Chemistry from the University of Southern Indiana. Mr. Adams makes valuable contributions to the InMed Board based on his extensive international business development experience in a wide range of disease categories and contributions to growing several organizations across the pharmaceutical and medical device arenas.
- Eric Hsu
Eric Hsu于2018年3月加入InMed，担任临床前研发负责人。他在临床前研究方面拥有超过22年的科学领导经验，包括台式研究、配方开发和制造工艺开发，以及专利申请、供应商合同谈判和执行以及研究合作伙伴关系。他还负责扩展产品管线，管理研发预算和时间表。在加入InMed之前，他曾在EnGene Inc.担任多个职位，包括研究部副总裁以及科学事务与运营部副总裁。许博士在多伦多大学医学生物物理系获得博士学位，在麦吉尔大学获得学士学位。
Eric Hsu joined InMed as head of Preclinical Research and Development in March 2018. He has more than 22 years of scientific leadership experience in preclinical research, including benchtop research, formulation development and manufacturing process development, as well as patent prosecution, vendor contract negotiations and execution, and research partnerships. He is also responsible for expanding product pipelines and managing R&D budgets and timelines. Prior to joining InMed, he held various positions within EnGene Inc., including V.P. of Research and V.P. of Scientific Affairs and Operations. Dr. Hsu received his Doctorate from the Department of Medical Biophysics at the University of Toronto and his Bachelor's degree from McGill University.- Eric Hsu于2018年3月加入InMed，担任临床前研发负责人。他在临床前研究方面拥有超过22年的科学领导经验，包括台式研究、配方开发和制造工艺开发，以及专利申请、供应商合同谈判和执行以及研究合作伙伴关系。他还负责扩展产品管线，管理研发预算和时间表。在加入InMed之前，他曾在EnGene Inc.担任多个职位，包括研究部副总裁以及科学事务与运营部副总裁。许博士在多伦多大学医学生物物理系获得博士学位，在麦吉尔大学获得学士学位。
- Eric Hsu joined InMed as head of Preclinical Research and Development in March 2018. He has more than 22 years of scientific leadership experience in preclinical research, including benchtop research, formulation development and manufacturing process development, as well as patent prosecution, vendor contract negotiations and execution, and research partnerships. He is also responsible for expanding product pipelines and managing R&D budgets and timelines. Prior to joining InMed, he held various positions within EnGene Inc., including V.P. of Research and V.P. of Scientific Affairs and Operations. Dr. Hsu received his Doctorate from the Department of Medical Biophysics at the University of Toronto and his Bachelor's degree from McGill University.
- Michael Woudenberg
Michael Woudenberg于2018年加入Inmed Pharmaceuticals Inc.，拥有20多年成功的药物开发、工艺工程、良好生产规范制造和领导经验。Woudenberg先生此前曾担任公司化学、制造和控制高级副总裁，直至2022年7月被任命为公司首席运营官。在2018年加入Inmed Pharmaceuticals Inc.之前，Woudenberg先生曾在3M、Cardiome Pharma、Arbutus生物制药等公司担任多个职位，最近担任Phyton Biotech，LLC的董事总经理。他的经验包括从实验室/临床前产品到临床开发的各个阶段，再到经过验证并成功批准和检查的商业原料药和药物产品的工艺和制剂开发。此外，他在监管检查（例如FDA、欧洲、澳大利亚、韩国、日本、加拿大）及其从临床到商业化生产批准产品的相关化学、制造和控制要求方面拥有丰富的经验。Woudenberg先生在加拿大安大略省伦敦西部大学获得理学、化学学士学位和工程科学、化学学士学位。
Michael Woudenberg joined Inmed Pharmaceuticals Inc. in 2018 with more than 20 years of successful drug development, process engineering, Good Manufacturing Practice manufacturing and leadership experience. Mr. Woudenberg previously served as the company's Senior Vice President of Chemistry, Manufacturing and Controls, until his appointment as the company's Chief Operating Officer in July 2022. Prior to joining Inmed Pharmaceuticals Inc. in 2018, Mr. Woudenberg held various positions within 3M, Cardiome Pharma, Arbutus Biopharma and most recently as the Managing Director of Phyton Biotech, LLC. His experience includes process and formulation development from lab/preclinical products through the various stages of clinical development to validated and successfully approved and inspected commercial APIs and drug products. Additionally, he has extensive experience with regards to regulatory inspections (e.g., FDA, European, Australian, Korean, Japanese, Canadian) and their related chemistry, manufacturing and control requirements from clinical to commercial production of approved products. Mr. Woudenberg received his Bachelor of Science, Chemistry, and Bachelor of Engineering Science, Chemical, at Western University of London, Ontario, Canada.- Michael Woudenberg于2018年加入Inmed Pharmaceuticals Inc.，拥有20多年成功的药物开发、工艺工程、良好生产规范制造和领导经验。Woudenberg先生此前曾担任公司化学、制造和控制高级副总裁，直至2022年7月被任命为公司首席运营官。在2018年加入Inmed Pharmaceuticals Inc.之前，Woudenberg先生曾在3M、Cardiome Pharma、Arbutus生物制药等公司担任多个职位，最近担任Phyton Biotech，LLC的董事总经理。他的经验包括从实验室/临床前产品到临床开发的各个阶段，再到经过验证并成功批准和检查的商业原料药和药物产品的工艺和制剂开发。此外，他在监管检查（例如FDA、欧洲、澳大利亚、韩国、日本、加拿大）及其从临床到商业化生产批准产品的相关化学、制造和控制要求方面拥有丰富的经验。Woudenberg先生在加拿大安大略省伦敦西部大学获得理学、化学学士学位和工程科学、化学学士学位。
- Michael Woudenberg joined Inmed Pharmaceuticals Inc. in 2018 with more than 20 years of successful drug development, process engineering, Good Manufacturing Practice manufacturing and leadership experience. Mr. Woudenberg previously served as the company's Senior Vice President of Chemistry, Manufacturing and Controls, until his appointment as the company's Chief Operating Officer in July 2022. Prior to joining Inmed Pharmaceuticals Inc. in 2018, Mr. Woudenberg held various positions within 3M, Cardiome Pharma, Arbutus Biopharma and most recently as the Managing Director of Phyton Biotech, LLC. His experience includes process and formulation development from lab/preclinical products through the various stages of clinical development to validated and successfully approved and inspected commercial APIs and drug products. Additionally, he has extensive experience with regards to regulatory inspections (e.g., FDA, European, Australian, Korean, Japanese, Canadian) and their related chemistry, manufacturing and control requirements from clinical to commercial production of approved products. Mr. Woudenberg received his Bachelor of Science, Chemistry, and Bachelor of Engineering Science, Chemical, at Western University of London, Ontario, Canada.
- Netta Jagpal
Netta Jagpal加入InMed，在主要在生物技术行业担任财务领导职务方面拥有超过20年的经验。在加入InMed之前，Jagpal女士曾在D 波浪系统 Inc.（NYSE：QBTS）担任财务报告与合规副总裁，领导财务团队完成首次公开募股流程。在加入D Wave之前，Netta在Zymeworks Inc.（NYSE：ZYME）工作了11年，这是一家总部位于温哥华的领先临床阶段生物制药公司，担任过多个财务职务，包括高级总监、财务&公司财务总监。Netta此前还曾在Angiotech Pharmaceuticals，Inc.（NASDAQ：ANP）和安永会计师事务所任职。Netta是不列颠哥伦比亚省特许会计师协会的特许专业会计师，拥有Simon Fraser大学会计和组织行为学工商管理学士学位。
Netta Jagpal joined InMed with over 20 years of experience in financial leadership roles, primarily in the biotech industry. Prior to InMed, Ms. Jagpal served as Vice President, Financial Reporting & Compliance for D Wave Systems Inc. (NYSE: QBTS) where she led a finance team through the initial public offering process. Prior to D Wave, Netta spent 11 years at Zymeworks Inc. (NYSE: ZYME), a leading Vancouver based clinical stage biopharmaceutical company, in various financial roles including Senior Director, Finance & Corporate Controller. Netta has also previously held roles at Angiotech Pharmaceuticals, Inc. (NASDAQ: ANP) and Ernst & Young. Netta is a Chartered Professional Accountant with the Institute of Chartered Accountants of British Columbia and holds a Bachelor of Business Administration degree in Accounting and Organization Behavior from Simon Fraser University.- Netta Jagpal加入InMed，在主要在生物技术行业担任财务领导职务方面拥有超过20年的经验。在加入InMed之前，Jagpal女士曾在D 波浪系统 Inc.（NYSE：QBTS）担任财务报告与合规副总裁，领导财务团队完成首次公开募股流程。在加入D Wave之前，Netta在Zymeworks Inc.（NYSE：ZYME）工作了11年，这是一家总部位于温哥华的领先临床阶段生物制药公司，担任过多个财务职务，包括高级总监、财务&公司财务总监。Netta此前还曾在Angiotech Pharmaceuticals，Inc.（NASDAQ：ANP）和安永会计师事务所任职。Netta是不列颠哥伦比亚省特许会计师协会的特许专业会计师，拥有Simon Fraser大学会计和组织行为学工商管理学士学位。
- Netta Jagpal joined InMed with over 20 years of experience in financial leadership roles, primarily in the biotech industry. Prior to InMed, Ms. Jagpal served as Vice President, Financial Reporting & Compliance for D Wave Systems Inc. (NYSE: QBTS) where she led a finance team through the initial public offering process. Prior to D Wave, Netta spent 11 years at Zymeworks Inc. (NYSE: ZYME), a leading Vancouver based clinical stage biopharmaceutical company, in various financial roles including Senior Director, Finance & Corporate Controller. Netta has also previously held roles at Angiotech Pharmaceuticals, Inc. (NASDAQ: ANP) and Ernst & Young. Netta is a Chartered Professional Accountant with the Institute of Chartered Accountants of British Columbia and holds a Bachelor of Business Administration degree in Accounting and Organization Behavior from Simon Fraser University.